OA12819A - Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. - Google Patents

Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. Download PDF

Info

Publication number
OA12819A
OA12819A OA1200400307A OA1200400307A OA12819A OA 12819 A OA12819 A OA 12819A OA 1200400307 A OA1200400307 A OA 1200400307A OA 1200400307 A OA1200400307 A OA 1200400307A OA 12819 A OA12819 A OA 12819A
Authority
OA
OAPI
Prior art keywords
docetaxel
doxorubicin
cyclophosphamide
cancer
dose
Prior art date
Application number
OA1200400307A
Other languages
English (en)
Inventor
Hichem Chakroun
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of OA12819A publication Critical patent/OA12819A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200400307A 2002-05-17 2003-05-15 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. OA12819A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
OA12819A true OA12819A (en) 2006-07-10

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400307A OA12819A (en) 2002-05-17 2003-05-15 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer.

Country Status (28)

Country Link
US (2) US20040014694A1 (ru)
EP (1) EP1507573A1 (ru)
JP (1) JP4773719B2 (ru)
KR (1) KR20050000544A (ru)
CN (1) CN1652845A (ru)
AU (1) AU2003244646B2 (ru)
BR (1) BR0310026A (ru)
CA (1) CA2486124A1 (ru)
CR (1) CR7575A (ru)
EC (1) ECSP045433A (ru)
HR (1) HRPK20041072B3 (ru)
IL (1) IL165214A0 (ru)
MA (1) MA27417A1 (ru)
ME (2) ME00055B (ru)
MX (1) MXPA04010640A (ru)
MY (1) MY146533A (ru)
NO (1) NO20045370L (ru)
NZ (1) NZ535992A (ru)
OA (1) OA12819A (ru)
PA (1) PA8574001A1 (ru)
RS (1) RS96304A (ru)
RU (1) RU2321396C2 (ru)
TN (1) TNSN04217A1 (ru)
TW (1) TWI374741B (ru)
UA (1) UA81628C2 (ru)
UY (1) UY27812A1 (ru)
WO (1) WO2003097164A1 (ru)
ZA (1) ZA200408549B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344899T3 (es) * 2003-09-25 2010-09-09 Astellas Pharma Inc. Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080085879A1 (en) * 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
BR112013025410A2 (pt) * 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
SG10201809411PA (en) * 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
RU2736045C2 (ru) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Способ лечения рака, ассоциированного с мутацией ras
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
EP3366296B1 (en) * 2015-10-22 2020-01-15 Universidade De Santiago De Compostela Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash)
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US20190177430A1 (en) * 2016-08-24 2019-06-13 The Wistar Institute Of Anatomy And Biology Methods of Treating Cancers With Chemotherapy With Reduced Toxicity
US11491147B2 (en) * 2016-10-03 2022-11-08 Indiana University Research And Technology Corporation Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
HRP20240069T1 (hr) 2017-03-02 2024-03-29 Genentech, Inc. Adjuvantno liječenje her2-pozitivnog raka dojke
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
AU2019288813B2 (en) 2018-06-22 2023-06-29 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
KR20050000544A (ko) 2005-01-05
ZA200408549B (en) 2006-01-25
JP4773719B2 (ja) 2011-09-14
MY146533A (en) 2012-08-15
CA2486124A1 (en) 2003-11-27
RS96304A (en) 2006-10-27
TNSN04217A1 (en) 2007-03-12
AU2003244646B2 (en) 2008-08-07
IL165214A0 (en) 2005-12-18
TW200407152A (en) 2004-05-16
MEP16308A (en) 2010-06-10
BR0310026A (pt) 2005-02-15
NO20045370L (no) 2004-12-08
NZ535992A (en) 2008-11-28
AU2003244646A1 (en) 2003-12-02
WO2003097164A1 (en) 2003-11-27
HRP20041072A2 (en) 2005-06-30
MA27417A1 (fr) 2005-07-01
CR7575A (es) 2006-05-10
US20040014694A1 (en) 2004-01-22
MXPA04010640A (es) 2005-08-16
TWI374741B (en) 2012-10-21
JP2005529925A (ja) 2005-10-06
HRPK20041072B3 (en) 2007-07-31
EP1507573A1 (en) 2005-02-23
PA8574001A1 (es) 2003-12-19
US20070265213A1 (en) 2007-11-15
RU2321396C2 (ru) 2008-04-10
CN1652845A (zh) 2005-08-10
ME00055B (me) 2010-10-10
UY27812A1 (es) 2003-11-28
UA81628C2 (ru) 2008-01-25
ECSP045433A (es) 2005-01-03
RU2004136984A (ru) 2005-06-27

Similar Documents

Publication Publication Date Title
OA12819A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer.
RU2587013C2 (ru) Комбинированная химиотерапия
CN1303294A (zh) 抗肿瘤剂
JP2002504511A5 (ru)
CN111902147A (zh) 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
JP2008503579A (ja) 癌の化学療法
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
EP1206256B1 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
JPH10511108A (ja) テモゾロミドおよびシスプラチンを含む進行ガンに対する組み合わせ治療
US20050215604A1 (en) Combination therapies with epothilones and carboplatin
US20080318880A1 (en) Neoadjuvant treatment of Breast Cancer
US20020013362A1 (en) Paclitaxel treatment regimen for metastatic melanoma
RU2284818C2 (ru) Комбинированная химиотерапия
CN114642666A (zh) 含有帕博西尼和紫杉醇的药物组合物及应用
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
JP2006516533A (ja) アントラサイクリンおよびタキサンによる転移性乳癌の治療
KR20010102402A (ko) 상승작용성 항종양 조성물
JP2007523825A (ja) 乳癌治療のためのｄｐｐｅと他の化学療法剤との併用
Nabholtz Share this story: RELATED ARTICLES
ZA200607806B (en) Combination therapies with epothilones and carboplatin
MXPA06010921A (en) Combination therapies with epothilones and carboplatin